Q-omics provides the consensus-scored CYB561D1 profile across patient tissues and cancer cell-line models. CYB561D1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, CYB561D1 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, CYB561D1 RNA expression shows 19,411 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight HNSC, COAD, and ACC as cancer lineages where CYB561D1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CYB561D1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CYB561D1 survival associations across molecular data types. CYB561D1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CYB561D1 RNA expression–survival associations across cancer types. High CYB561D1 expression shows unfavorable associations in KICH, ACC and LIHC, but favorable associations in HNSC, PAAD and KIRC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for CYB561D1 RNA expression.
This table summarizes CYB561D1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for CYB561D1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CYB561D1 shows lower tumor expression in COAD, LUAD, BRCA and THCA and higher tumor expression in LIHC and CHOL. The COAD box plot shows higher CYB561D1 RNA expression in normal versus tumor tissue (log2 FC = −0.708, t-test p < 0.001).
This table shows molecular features associated with CYB561D1 in patient tissues and cancer cell lines. In patient samples, CYB561D1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, CYB561D1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
